QXO Appoints Eric Nelson as Chief Information Officer
GREENWICH, Conn.–(BUSINESS WIRE)–QXO, Inc. (NYSE: QXO) today announced that Eric Nelson has been appointed chief information officer, effective July... Read more.
Specops Now Offered Through GuidePoint Security
New collaboration offers GuidePoint Security customers access to password management and authentication solutions, which protect business data by blocking weak and... Read more.
NRG Energy Announces Appointment of Brad Bentley as President, NRG Consumer
HOUSTON–(BUSINESS WIRE)–NRG Energy, Inc. (NYSE:NRG) today announced the appointment of Brad Bentley as President, NRG Consumer, effective July 28, 2025.... Read more.
Blue Sage Capital Invests in Clean Scapes Landscaping
AUSTIN, Texas–(BUSINESS WIRE)–Blue Sage Capital (“Blue Sage”) is pleased to announce its recently completed investment in Clean Scapes Enterprises,... Read more.
ClearOne, Inc. Clarifies Dividend Date for Special Stock Dividend
SALT LAKE CITY–(BUSINESS WIRE)–On June 30, 2025, ClearOne (NASDAQ: CLRO) announced that its Board of Directors had declared a one-time special stock... Read more.
Eaton continues to progress on its sustainability targets, as outlined in new report
Company has reduced GHG emissions 35% since 2018 Achieved 83% of waste target and surpassed water target Reported 76% of 2024 net sales were from products and solutions... Read more.
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer... Read more.
Spire Global Launches Aircraft Exposure Analytics for Weather-Related Aircraft Risk
Powered by actual aircraft utilization based on global ADS-B data and Significant Meteorological Information alerts, Aircraft Exposure Analytics measures aircraft... Read more.
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
Doravirine/islatravir would be the first FDA-approved two-drug regimen without an integrase inhibitor that demonstrated non-inferior efficacy and a generally comparable... Read more.
Behavox AI cuts compliance teams’ investigation times by over 40%
Intelligent Archive drives cost efficiency and ROI by unifying data and applying specialized LLM LONDON & MONTREAL–(BUSINESS WIRE)–Behavox, the leading... Read more.